4 days Ago bluebird bio ( NASDAQ: BLUE ) said it has received an unsolicited offer from Ayrmid Pharma to buy the company for a sum significantly higher than a take-private deal from private equity firms The Carlyle Group (CG ) and SK Capital Partners.
